Tradename
Nandurabolin
Generic Name
Nandrolone decanoate
Category
Endocrine System
Form
Ampoule
Composition
Active Ingredients
Nandrolone decanoate...........25 or 50 mg/ml
Excipients
Benzyl benzoate, arachis oil
Description
Properties/Actions
Pharmacodynamics
Nandrolone is chemically related to testosterone and shows enhanced anabolic and a reduced androgenic activity.
In humans Nandurabolin has been shown to positively influence calcium metabolism and to increase bone mass in osteoporosis.
Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C17 alpha-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.

Pharmacokinetics
Nandrolone decanoate is slowly released from the injection site into the blood with a half-life of 6 days. The e.ster is rapidly hydrolysed to nandrolone in the blood with a half-life of one hour or less. The half-life for the combined process of hydrolysis of nandrolone decanoate and of distribution and elimination of nandrolone is 4.3 hours.
Nandrolone is metabolised by the liver. 19-norandrosterone, 19-noretiocholanolone and 19-norepiandrosterone have been identified as metabolites in the urine. It is not known whether these metabolites display a pharmacological action
Indications
Nandurabolin is indicated for use in osteoperosis in post-menopausal women.
Established osteoperosis should have been diagnosed by the following parameters:
  • Crush or wedge fractures of the vertebrae.
  • Other osteoporotic fractures.
  • Established reduction in bone mineral content as measured by accepted BMC measurements.
Contraindications
Nandurabolin solution for injection is contraindicated in:
  • Pregnancy , nursing mothers  and pediatrics (See "Warnings").
  • Porphyria.
  • Allergies to any of the components.
  • Known or suspected carcinoma of the prostate or mammary carcinoma in the male.
Drug Interactions
Anabolic steroids may improve glucose tolerance and decrease the need for insulin or other antidiabetic drugs in diabetics.
Side Effects/Adverse Effects
Nandurabolin at the recommended dosages is unlikely to produce virilising effects.
High dosages, prolonged treatment and/or too frequent administration may cause:
  • Virilisation which appears in sensitive women as hoarseness, acne, hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in long-lasting, sometimes irreversible deepening of the voice.
  • Amenorrhoea and inhibition of spermatogenesis.
  • Premature epiphyseal closure.
  • Sodium and water retention.
  • Abnormal liver function tests have been reported in patients treated with (high doses) of Nandurabolin.
  • Liver tumours have been reported occasionally on prolonged treatment with orally active C17-alpha alkylated anabolic steroids. A relationship between liver tumours and non-C17-alkylated injectable steroids, such as nandrolone esters, appears to be highly unlikely, but cannot be absolutely excluded.
Pregnancy & Lactation
Nandurabolin is contraindicated during pregnancy and lactation because of possible masculinisation of the foetus.
Injections preserved with benzyl alcohol should not be administered to neonates , infants, pregnant women or nursing mothers. Benzyl alcohol has been associated with serious adverse events and death, particularly in pediatric patients. Preservative-free should be used in these populations.
Dosage & Administration
Post-menopausal women: 50 mg every three weeks, by deep muscular injection.
The duration of treatment depends on the clinical response and the possible occurrence of side effects.
We would recommend that the effectiveness of therapy be monitored with the appropriate methods for osteoporosis on a 6-12 monthly basis.
Overdosage
The acute toxicity of nandrolone decanoate in animals is very low. There are no reports of acute overdosage with Nandurabolin in humans.
Warnings
Nandurabolin solution for injection is contraindicated for use in pregnant women, nursing mohters, and pediatrics.
Injections preserved with benzyl alcohol should not be administered to neonates , infants, pregnant women or nursing mothers. Benzyl alcohol has been associated with serious adverse events and death, particularly in pediatric patients. Preservative-free should be used in these populations.
If signs of virilisation develop, discontinuation of the treatment should be considered.
Patients, especially the elderly, with the following conditions should be monitored:
  • Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may occasionally induce sodium and water retention.
  • Incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure; skeletal metastases, since anabolic steroids may induce hypercalcaemia and hypercalciuria in these patients.
  • Liver dysfunction; caution should be used in patients with severe hepatic impairment and Nandurabolin should only be used if the benefits outweigh the risks.
  • Diabetes mellitus.
  • Nandurabolin contains Arachis oil (peanut oil) and should not be taken by patients known to be allergic to peanuts. As there is a possible relationship between allergy to peanuts and allergy to soya, patients with soya allergy should also avoid Nandurabolin use.
  • The use of anabolic steroids to enhance athletic ability may carry severe risks to the user's health and should be discouraged.
Notes
Storage
Do not store above 30°C, and do not refrigerate.
Packaging
Box of 1 ml ampoule.
Manufacturer
Nile Co. for Pharmaceuticals and Chemical Ind.
Date Added/Updated
4th March 2012 3:16pm

Miscellaneous

Share This!

Respected Sites

drugs.com

rxlist.com

rxwiki.com

Need Help?

on-call support